2024-04-24 13:34:34 ET
Summary
- Kiniksa Pharmaceuticals reported strong Q1 2024 results, with net sales of Arcalyst growing 85% YoY and 11% sequentially.
- Arcalyst's strong performance has driven a $10 million increase in the full-year net sales guidance range.
- Kiniksa plans to develop abiprubart for the treatment of Sjogren's syndrome, with a large phase 2b trial expected to start in the second half of the year.
- With long development timelines for abiprubart, Kiniksa faces a very dry period for its clinical pipeline and the upside in the next 2-3 years depends on Arcalyst.
- With a strong balance sheet and management expecting positive cash flow this year, we could see Kiniksa in-license additional clinical candidates in the following quarters.
Kiniksa Pharmaceuticals ( KNSA ) reported Q1 2024 results that showed strong sequential and year-over-year net sales growth of Arcalyst, and the strong year-to-date performance prompted a $10 million increase in the full-year guidance range. The expanded sales force, good payer coverage and positive experience of patients and physicians are driving Arcalyst’s strong uptake....
Read the full article on Seeking Alpha
For further details see:
Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape